Quality-Adjusted Life Years (QALYS) for Inotuzumab Ozogamicin versus Investigators Choice (IC) for relapsed/refractory b-cell acute lymphoblastic leukaemia (R/R B-ALL)

Authors:

Batteson R, Critchlow S, Barnes A, Glah D, Smith A, Lang K and Su Y.

Publication type:

Poster PCN205

Conference name:

20th International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Annual European Congress

Citation:

Batteson R, Critchlow S, Barnes A, Glah D, Smith A, Lang K and Su Y. Quality-Adjusted Life Years (QALYS) for Inotuzumab Ozogamicin versus Investigators Choice (IC) for relapsed/refractory b-cell acute lymphoblastic leukaemia (R/R B-ALL). 20th International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Annual European Congress. Glasgow: Scotland, 2017.

Link to publication ⟶

⟵ Back to Search Results

By continuing to browse or by clicking "Accept All Cookies" you agree to the storing of first and third-party cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.
Cookie Policy
Accept All Cookies
By continuing to browse or by clicking "Accept All Cookies" you agree to the storing of first and third-party cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.
Cookie Policy
Accept All Cookies